- Feel an increase in energy.
- Less joint pain.
- Lessens Multiple Sclerosis symptoms.
A recent study carried out at the Department of Nutritional Sciences, University of Toronto, has tried to establish whether vitamin D3 has any therapeutic potential for multiple sclerosis.
The researchers, Samantha M Kimball, Melanie R Ursell, Paul O’Connor and Reinhold Vieth, studied whether large doses of concentrated vitamin D caused hypercalcemia, a large build up of calcium in the system, and if not, whether the vitamin D could help control symptoms of multiple sclerosis.
Hypercalcemia is the result of vitamin D toxicity and can present itself in many symptoms such as fatigue, weakness, sickness and kidney stones.
The objective of the study was to characterize the calcemic response to specific serum 25(OH)D concentrations. Over a 28 week period, 12 patients in an active phase of multiple sclerosis were given 1200 mg elemental Ca/d along with progressively increasing doses of vitamin D3: from 700 to 7000 µg/wk (from 28 000 to 280 000 IU/wk).
The results showed that the mean (± SD) serum concentrations of vitamin D initially were 78 ± 35 nmol/L and rose to 386 ± 157 nmol/L (P < 0.001). Serum calcium concentrations and the urinary ratio of calcium to creatinine neither increased in mean values nor exceeded reference values for any participant (2.1–2.6 mmol/L and <1.0, respectively).
[pullquote_left]“The data supports the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.”[/pullquote_left]
The liver enzymes, serum creatinine, electrolytes, serum protein, and parathyroid hormone did not change according to Bonferroni repeated-measures statistics, although parathyroid hormone did decline significantly according to the paired t test. Disease progression and activity were not affected, but the number of gadolinium-enhancing lesions per patient (assessed with a nuclear magnetic brain scan) decreased from the initial mean of 1.75 to the end-of-study mean of 0.83 (P = 0.03).
The conclusions drawn from these results are that the patients’ serum 25(OH)D concentrations reached twice the top of the physiologic range without eliciting hypercalcemia or hypercalciuria. “The data supports the feasibility of pharmacologic doses of vitamin D3 for clinical research, and they provide objective evidence that vitamin D intake beyond the current upper limit is safe by a large margin.”
[box_info] Vitamin D and Multiple Sclerosis.